Aligos Therapeutics (NASDAQ:ALGS - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $70.00 price objective on the stock.
Aligos Therapeutics Stock Performance
ALGS stock traded down $1.24 during trading on Monday, hitting $5.25. The stock had a trading volume of 207,161 shares, compared to its average volume of 175,629. Aligos Therapeutics has a 1-year low of $5.12 and a 1-year high of $46.80. The stock has a market cap of $32.07 million, a price-to-earnings ratio of -0.39 and a beta of 2.72. The company's 50 day moving average price is $17.15 and its two-hundred day moving average price is $20.02.
Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($13.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.63) by ($10.45). The firm had revenue of $0.63 million for the quarter, compared to analysts' expectations of $0.43 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the previous year, the company posted ($5.50) EPS. As a group, sell-side analysts forecast that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.
Institutional Trading of Aligos Therapeutics
A number of hedge funds have recently added to or reduced their stakes in ALGS. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Aligos Therapeutics by 48.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 325,000 shares of the company's stock worth $12,948,000 after acquiring an additional 106,187 shares during the period. Trexquant Investment LP acquired a new position in Aligos Therapeutics during the fourth quarter worth approximately $2,751,000. Avantax Advisory Services Inc. purchased a new position in Aligos Therapeutics during the fourth quarter worth approximately $1,218,000. Geode Capital Management LLC boosted its holdings in shares of Aligos Therapeutics by 13.3% in the 4th quarter. Geode Capital Management LLC now owns 27,253 shares of the company's stock valued at $1,086,000 after purchasing an additional 3,197 shares during the last quarter. Finally, Drive Wealth Management LLC purchased a new stake in shares of Aligos Therapeutics during the 4th quarter valued at $916,000. 60.43% of the stock is owned by institutional investors and hedge funds.
Aligos Therapeutics Company Profile
(
Get Free Report)
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
See Also
Before you consider Aligos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.
While Aligos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
